Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Buy" from Brokerages

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been given a consensus recommendation of "Buy" by the eight analysts that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $19.43.

REPL has been the subject of a number of research reports. HC Wainwright raised their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their target price on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, BMO Capital Markets increased their price target on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd.

Replimune Group Trading Down 0.8 %

REPL stock traded down $0.06 during midday trading on Tuesday, hitting $7.71. The stock had a trading volume of 1,352,895 shares, compared to its average volume of 895,800. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The firm has a market cap of $593.79 million, a P/E ratio of -2.51 and a beta of 0.68. The business has a fifty day moving average price of $9.45 and a two-hundred day moving average price of $11.52. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, sell-side analysts predict that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sterling Capital Management LLC raised its holdings in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares during the last quarter. US Bancorp DE grew its position in Replimune Group by 582.6% in the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after purchasing an additional 3,921 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after buying an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd lifted its position in shares of Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after buying an additional 8,183 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Replimune Group by 897.2% in the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock worth $902,000 after buying an additional 7,913 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.